Æ®·»Å»¼¹æÁ¤400(ÆæÅå½ÃÇʸ°) Trentral SR Tab.400mg
Àü¹®ÀǾàǰ | ±Þ¿©
|
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
À广ÇüÀÇ Èò»ö ¼¹æ¼º Çʸ§ÄÚÆÃÁ¤
Á¦Á¶È¸»ç
(ÁÖ)Çѵ¶
ÆÇ¸Åȸ»ç
(ÁÖ)Çѵ¶
Çã°¡Á¤º¸
Á¤»ó
(1980.11.08)
BIT ¾àÈ¿ºÐ·ù
¼øÈ¯°³¼±Á¦ (Circulatory Improvement Agents)
º¹ÁöºÎºÐ·ù
219[±âŸÀÇ ¼øÈ¯°è¿ë¾à ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
652101370[A07402791] \190 ¿ø/1Á¤(2017.02.01) (ÇöÀç¾à°¡) \190 ¿ø/1Á¤(2014.03.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Pentoxifylline / C04AD03
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
¹é´ç ,
»êÈÆ¼Åº ,
½ºÅ׾Ƹ£»ê¸¶±×³×½· ,
¾Æ¶óºñ¾Æ°í¹« ,
Àû»ö3È£ ,
ÅÅÅ© ,
Æ÷ºñµ· ,
Æú¸®¿¡Æ¿·»±Û¸®ÄÝ 8000 ,
Æú¸®¿¡Æ¿·»±Û¸®ÄÝ6000 ,
È÷µå·Ï½Ã¿¡Æ¿ ¼¿·ê·Î¿À½º ,
È÷ÇÁ·Î¸á·Î¿À½º
º´¿ë±Ý±â
Á¦Ç°º° ÀӺαݱ⠰í½Ã
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
¼ººÐ¸í
¼ººÐÄÚµå
±Ý±âµî±Þ
°í½Ã¹øÈ£
°í½ÃÀÏÀÚ
ºñ°í
pentoxifylline
210802ATR
2
20200061
20200710
ÀӺο¡ ´ëÇÑ ÃæºÐÇÑ »ç¿ë °æÇè ¾øÀ½.
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
652101370[A07402791]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\190 ¿ø/1Á¤(2017.02.01) (ÇöÀç¾à°¡)
\190 ¿ø/1Á¤(2014.03.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
À广ÇüÀÇ Èò»ö ¼¹æ¼º Çʸ§ÄÚÆÃÁ¤ [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
500Á¤/º´, 60Á¤(10Á¤/PTPX6)
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
Æ÷ÀåÇüÅÂ
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
400¹Ð¸®±×·¥
30 Á¤
º´
8806521013701
8806521013732
400¹Ð¸®±×·¥
500 Á¤
º´
8806521013701
8806521013725
400¹Ð¸®±×·¥
60 Á¤
PTP
8806521013701
8806521013718
ÁÖ¼ººÐÄÚµå
210802ATR
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
1. ³ú¼øÈ¯Àå¾Ö(ÇãÇ÷ ¹× ³úÁ¹ÁßÈÄÁõ»ó, ¾îÁö·¯¿ò¡¤µÎÅ롤°Ç¸ÁÁõ µî ³úµ¿¸Æ°æÈÁõ Áõ»ó)
2. ´«ÀÇ Ç÷·ù¼øÈ¯Àå¾Ö
3. ¸»Ãʵ¿¸Æ¼øÈ¯Àå¾Ö(°£Ç漺ÆÄÇà, È޽Ľà µ¿Åë, ´ç´¢º´¼ºÇ÷°üº´Áõ, À§ÃàÁõ, Ç÷°ü½Å°æº´Áõ)
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : ÆæÅå½ÃÇʸ°À¸·Î¼ 1ȸ 400§· 1ÀÏ 2-3ȸ ½ÄÈÄ¿¡ ¼Ò·®ÀÇ À½·á¿Í ÇÔ²² °æ±¸Åõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
±Ý±â
1) ÀÌ ¾à ¶Ç´Â ´Ù¸¥ ¸Þƿũ»êƾ°è ¾à¹°¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ±Þ¼º ½É±Ù°æ»ö ȯÀÚ
3) ´ë·® ÃâÇ÷ ȯÀÚ(ÃâÇ÷Áõ°¡ÀÇ À§ÇèÀÌ Àִ ȯÀÚ)
4) ±¤¹üÀ§ÇÑ ¸Á¸· ÃâÇ÷ ȯÀÚ(ÃâÇ÷Áõ°¡ÀÇ À§ÇèÀÌ Àִ ȯÀÚ)
5) ÄÉÅä·Ñ¶ôÀ» Åõ¿©¹Þ°í Àִ ȯÀÚ
½ÅÁßÅõ¿©
1) ÁßÁõÀÇ ½ÉºÎÁ¤¸Æ ȯÀÚ
2) ÀúÇ÷¾Ð, °üµ¿¸ÆÁúȯ ȯÀÚ
3) ½Å±â´É Àå¾Ö ȯÀÚ(Å©·¹¾ÆÆ¼´Ñ Ŭ¸®¾î·±½º°¡ 30ml/min ÀÌÇÏ)
4) ÁßÁõÀÇ °£±â´É Àå¾Ö ȯÀÚ
5) Ç×ÀÀ°íÁ¦ Ä¡·á ¶Ç´Â ÀÀ°í Àå¾Ö µî¿¡ ÀÇÇØ ÃâÇ÷°æÇâÀÌ Áõ°¡µÈ ȯÀÚ
ÀÌ»ó¹ÝÀÀ
1) °ú¹ÎÁõ : ¶§¶§·Î ¼Ò¾ç°¨, ÇǺκӾîÁü, µÎµå·¯±â µîÀÌ ±×¸®°í °³Àο¡ µû¶ó Ç÷°ü½Å°æ¼º ºÎÁ¾, ±â°ü±â °æ·Ã, ½ÉÁö¾î ¼îÅ©¿Í °°Àº ÁßÁõÀÇ ¾Æ³ªÇʶô½Ã¼º/¾Æ³ªÆÈ¶ôÅäÀÌµå ¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¾Æ³ªÇʶô½Ã¼º/¾Æ³ªÆÈ¶ôÅäÀÌµå ¹ÝÀÀÀÌ ³ªÅ¸³ª¸é ÀÌ ¾àÀÇ Åõ¿©¸¦ Áï½Ã Áß´ÜÇϰí Àǻ翡°Ô ¾Ë·Á¾ß ÇÑ´Ù.
2) ¼Òȱâ°è : ¶§¶§·Î ½Ä¿åºÎÁø, ±¸¿ª, ±¸Åä, À§ºÎ ºÒÄè°¨, ¼³»ç, º¹±¸ ÆØ¸¸°¨, ±¸°¥, ´ã³¶¿°, µå¹°°Ô °¡½¿¾²¸², º¯ºñ, º¹Åë µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼øÈ¯±â°è : ¶§¶§·Î È£Èí°ï¶õ, ºÎÁ¾, µå¹°°Ô Çù½ÉÅë, Ç÷¾Ð°ÇÏ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ ºó¸ÆÀÌ º¸°íµÇ¾ú´Ù.
4) °£Àå : µå¹°°Ô ALT, AST »ó½ÂÀÌ, °³Àο¡ µû¶ó °£Àå³» ´ãÁó¿ïü, transaminase »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) Ç÷¾× : ƯÈ÷ ÃâÇ÷ °æÇâÀÌ Áõ°¡ÇÑ È¯ÀÚ¿¡¼´Â µå¹°°Ô ÃâÇ÷(ÇǺΠ¹× Á¡¸·, À§Àå°ü¿¡¼)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, °³Àο¡ µû¶ó¼´Â Ç÷¼ÒÆÇ°¨¼Ò°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
6) Á¤½Å½Å°æ°è : µå¹°°Ô ¹ßÇÑ, µÎÅë, ¾îÁö·¯¿ò, ºÒ¸é, ½Ã·Â ºÒ¼±¸í µîÀÇ ½Ã°¢Àå¾Ö, ºÒ¾È, º¸ÇàÀÌ»ó, ±¸À½Àå¾Ö, Á¹À½, ¿ì¿ï µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) È£Èí±â°è : µå¹°°Ô ºñÃâÇ÷, µ¶°¨Áõ»ó, ºñÃæÇ÷, Èĵο° µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ±âŸ : µå¹°°Ô ¿äÆó, °á¸·¿°, ¾ÏÁ¡, ÀÌÅë, ±Çۨ, BUN»ó½Â, ¼ÕÅé ºÎ·¯Áü, °í¹Ì, Ÿ¾×°ú´Ù, ¹éÇ÷±¸°¨¼Ò, ¹«±Õ¼º¼ö¸·¿° µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
9) ƯÈ÷ ÆæÅå½ÃÇʸ°À» °í¿ë·® Åõ¿©ÇßÀ» ¶§, ´ÙÀ½°ú °°Àº ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. : ¹ß¿, À§¾Ð°ú °°Àº À§Àå°ü ºÒÄè°¨, ÆØ¸¸°¨, ±¸¿ª, ±¸Åä, ¼³»ç µîÀÌ ºó¹øÇÏ°Ô ÀϾ¸é ¶§¶§·Î ºÎÁ¤¸Æ(¿¹: ºó¸Æ)ÀÌ ÀϾ ¼ö ÀÖ´Ù.
»óÈ£ÀÛ¿ë
1) Ç×ÀÀ°íÁ¦ ¶Ç´Â Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦¿Í º´¿ëÅõ¿© ¶Ç´Â ´Üµ¶Åõ¿©½Ã ÃâÇ÷, ÇÁ·ÎÆ®·Òºó½Ã°£ÀÇ ¿¬ÀåÀÌ º¸°íµÇ¾ú´Ù.
2) Àν¶¸° ¶Ç´Â °æ±¸¿ë Ç÷´ç°ÇÏÁ¦ÀÇ Ç÷´ç°ÇÏÀÛ¿ëÀ» Áõ°½Ãų ¼ö ÀÖÀ¸¹Ç·Î ´ç´¢º´ Ä¡·áÁ¦¸¦ Åõ¿©¹Þ°í Àִ ȯÀÚÀÇ °æ¿ì ÁÖÀDZí°Ô ¸ð´ÏÅ͸µÇÑ´Ù.
3) ÀÌ ¾àÀº °íÇ÷¾Ð ¾à¹° ¹× Ç÷¾ÐÀ» ³·Ãß´Â ´Ù¸¥ ¾à¹°µéÀÇ Ç÷¾Ð°ÇÏÀÛ¿ëÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
4) ÆæÅå½ÃÇʸ°°ú Å׿ÀÇʸ°À» º´¿ëÅõ¿©ÇÒ °æ¿ì ¸î¸î ȯÀÚ¿¡¼ Å׿ÀÇʸ°ÀÇ Ç÷Áß³óµµ°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¸ç µû¶ó¼ Å׿ÀÇʸ°¿¡ ÀÇÇÑ ÀÌ»ó¹ÝÀÀÀÌ Áõ°¡Çϰųª ½ÉÇØÁú ¼ö ÀÖ´Ù.
5) ÆæÅå½ÃÇʸ°Àº ÄÉÅä·Ñ¶ô°ú º´¿ëÅõ¿©½Ã ÃâÇ÷ ¹× ÇÁ·ÎÆ®·Òºó ½Ã°£ ¿¬ÀåÀÇ À§ÇèÀÌ ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
Off-label Usage
[Á¶È¸]
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
(µ¿¹° ½ÇÇè¿¡¼ ÁߵÀÇ À§Ç輺ÀÌ º¸°íµÇ¾úÀ¸³ª, ÀӺΠ´ë»ó ÀÓ»ó½ÃÇèÀº Á¦ÇÑÀûÀÌ´Ù. -Briggs G, et al. Drugs in Pregnancy and Lactation 7th edit. )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
º¹¾à¶óº§
À̹ÌÁö
º¹¾à¼³¸í
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù.
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù.
*
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù.
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
[ketorolac tromethamine]
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Pentoxifylline¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.
Pharmacology
Pentoxifylline¿¡ ´ëÇÑ Pharmacology Á¤º¸ Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Metabolism
Pentoxifylline¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
Protein Binding
Pentoxifylline¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 70%
Half-life
Pentoxifylline¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 0.4-0.8 hours
Pharmacokinetics
PentoxifyllineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
Èí¼ö : °æ±¸ : Àß Èí¼öµÊ
´ë»ç : °£¿¡¼ ÃÊȸÅë°úÈ¿°ú
¹Ý°¨±â : ¹Ìº¯Èü : 24-48ºÐ. ´ë»çü : 60-96ºÐ
Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 2-4 ½Ã°£ À̳»
¼Ò½Ç : ÁÖ·Î ½Å¹è¼³
Biotransformation
Pentoxifylline¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Toxicity
Pentoxifylline¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 =1385 mg/kg(orally in mice)
Drug Interactions
Pentoxifylline¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aminophylline Pentoxifylline increases the effect and toxicity of theophyllineDyphylline Pentoxifylline increases the effect and toxicity of theophyllineTheophylline Pentoxifylline increases the effect and toxicity of theophyllineOxtriphylline Pentoxifylline increases the effect and toxicity of theophyllineAnisindione Pentoxifylline increases the anticoagulant effectDicumarol Pentoxifylline increases the anticoagulant effectAcenocoumarol Pentoxifylline increases the anticoagulant effectWarfarin Pentoxifylline increases the anticoagulant effect
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Food Interaction
Pentoxifylline¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food to reduce irritation. Limit caffeine intake.
Drug Target
[Drug Target]
Description
Pentoxifylline¿¡ ´ëÇÑ Description Á¤º¸ A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem]
Dosage Form
Pentoxifylline¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet, extended release Oral
Drug Category
Pentoxifylline¿¡ ´ëÇÑ Drug_Category Á¤º¸ Free Radical ScavengersHematologic AgentsHemorrheologic AgentsPhosphodiesterase InhibitorsPlatelet Aggregation InhibitorsRadiation-Protective AgentsVasodilator Agents
Smiles String Canonical
Pentoxifylline¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
Smiles String Isomeric
Pentoxifylline¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
InChI Identifier
Pentoxifylline¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
Chemical IUPAC Name
Pentoxifylline¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
Drug-Induced Toxicity Related Proteins
PENTOXIFYLLINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein :Thrombomodulin Drug :pentoxifylline Toxicity :endothelial injury. [¹Ù·Î°¡±â] Replated Protein :Matrix metalloproteinaseDrug :pentoxifylline Toxicity :antifibrogenic action. [¹Ù·Î°¡±â] Replated Protein :Granzyme B Drug :pentoxifylline Toxicity :profound inhibitory effect. [¹Ù·Î°¡±â] Replated Protein :PerforinDrug :pentoxifylline Toxicity :profound inhibitory effect. [¹Ù·Î°¡±â] Replated Protein :Interleukin-6 Drug :pentoxifylline Toxicity :inflammation. [¹Ù·Î°¡±â] Replated Protein :Tumor necrosis factor (TNF alpha)Drug :pentoxifylline Toxicity :inflammation. [¹Ù·Î°¡±â] Replated Protein :Metalloproteinase inhibitor 1 Drug :pentoxifylline Toxicity :antifibrogenic action. [¹Ù·Î°¡±â] Replated Protein :Tumor necrosis factor (TNF beta)Drug :pentoxifylline Toxicity :inflammation. [¹Ù·Î°¡±â] Replated Protein :Interleukin-1 Drug :pentoxifylline Toxicity :inflammation. [¹Ù·Î°¡±â]
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-07-25
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ